medinsight catalogue

How to InstantlyAdvance Medicine

by 100 Years

The MedInsight Project

MedInsight Research Institute is a registered US 501(c)(3) nonprofit organization and a registered UK charity whose mission is to save lives and ease suffering.

In the US:MedInsight Research Institute211 East Lombard Street, #297Baltimore, MD 21202, USA

In the UK:MedInsight Research Institute TrustIsland West, Steep, Hampshire,GU32 1AE, United Kingdom

In Israel:MedInsight Research Institute27 Yitzchak Street, POB 386,Telz Stone 90840, Israel

Tel: +1-443-927-7755Fax: [email protected]

Tomorrow’s Medicinefor Anyone, Anytime, Anywhere

MedInsightr e s e a r c h i n s t i t u t e

®

Imagine:

... Pancreatic cancer patients living for yearsafter diagnosis – completely free of pain …

... Breast cancer patients going into completeremission for good – without commonchemotherapy and drastic, disfiguringsurgery …

... Heart disease, at any stage, getting undercomplete control …

... Multiple sclerosis going into complete,durable remission …

... Immune systems of Crohn’s diseasepatients normalizing, allowing normal lifeto people who have all but given up on allhope …

Imagine all this was not only true, butaffordable to all!

Imagine the cost of chronic diseasetreatment was lowered to the point thatevery man, woman and child could be fullycovered by national insurance withoutmortgaging our children’s future to pay forit. …

This is what we dream medicine will giveus in the next century. But in reality, it allcan happen today.

In fact, it could and should have been hereyesterday.

It’s true. The unimaginable amount ofsuffering and premature, often agonizing,deaths we experience today are all, in effect,

preventable.

Experts say this is the reason why:

The Missing GearImagine a luxury car with an advanced,

powerful engine under its hood and a set offantastic wheels to whisk it in comfort overthousands of miles …

… with a faulty, primitive gear connectingthe two!

That’s medicine.

Medicine is divided into two mainbranches: research medicine and medicalpractice. In theory, the first should beseamlessly feeding the second with ever-more efficient and affordable means to savelives and increase the quality of life ofmankind.

In reality, however, the two almost seemlike distant galaxies.

Research medicine is burgeoning withinformation. As you’ll see later in thisbooklet, virtually all the medical knowledgeto accomplish every single feat mentionedat the beginning of this text is already known.

And new discoveries are being made everysingle day.

But the fact is that less than 0.00015% ofusable medical research ever gets to help asingle patient.

Milestones in Medicine

Above:In 1962, Maurice Hugh FrederickWilkins (1916-2004) wasawarded the Nobel Prize forPhysiology or Medicine, for hisdiscoveries concerning themolecular structure of nucleicacids and its significance forinformation transfer in livingmaterial.

Left:A strand of DNA which containsthe genetic instructions for thedevelopment and function ofliving organisms. Geneticspromise to hold the key todisease prevention as well asever-more effective medicines.

03

The first domino piece to topple seems tobe that “we know too much”: researchmedicine publishes over 40,000 reports everyweek … while the average physician canread about 6! Wonderful knowledge isproduced but cannot be digested.

That leaves the responsibility oftransmitting data from lab to the bench tothe one entity that “lives in both worlds”:the drug maker.

Because the averagedoctor is so busy seeingpatients, he’s usuallyupdated on the newestand latest during theperiodical visits of thefriendlypharmaceutical

company representatives.

They, obviously, put their best footforward.

People love making the pharmaceuticalmanufacturers out to be the villains, but itshould be kept in mind that it costs up to$2 billion to push a drug through the mazeof FDA certification to the market. Everynew drug, in effect, is a huge gamble. Thisis why they use every trick in the book topush their merchandise.

With the drug companies being the almostexclusive conduit between research and

practice – both of information as well asactual drugs – it’s very understandable whythe discoveries that do pass from researchto the physician are only those that areprofitable for the drug industry.

But before one makes drug makers an easytarget, one must keep in mind the plain, ifunsavory truth:

Drug makers are not in the business ofsaving lives. They are in the business ofmaking and selling drugs – somethingthey do very well.

Saving lives is the job of doctors. It istheir role to use the drug companies toaccomplish that goal.

People would say medicine has “fallencaptive” into the hands of thepharmaceutical industry. In fact, doctorshave been more than willing “victims.”

But can you really blame them?

Easy and SafeJustified or not, the litigious society we

live in presents doctors with the risk ofmalpractice lawsuits. We call it the adventof justice. One of the side effects of thisjustice is to make doctors practice “defensivemedicine.”

Defensive medicine is first and foremoststicking to “accepted protocol.”

“Drugmakers arenot in thebusiness ofsaving lives.”


Above:The first ever Nobel Prize inPhysics was awarded in 1901 toWilhelm Conrad Röntgen (1845–1923) a German physicist, who,on November 8, 1895, producedand detected electromagneticradiation in a wavelength rangetoday known as x-rays. Thediscovery ushered a new era inthe diagnostics of everythingfrom skeletal issues to tumors.

Left:One of the first X-rayphotographs, taken by theWilhelm Conrad Roentgen ofhis wife's hand.

05

It means ordering a slew of expensivescreening tests that are often useless andmany times harmful. That drives the costof medicine sky-high – but it’s safe (for thedoctors). Accepted protocol is still the bestdefense in the court of law.

Accepted protocol is also an importantemotional crutch for doctors: doctors dealwith lives, some of which they lose due totheir own mistakes.

Psychologically, it is not an easy thing togo out on a limb on your own and face thatkind of responsibility.

Accepted protocolmay presentmediocre, limited,unimaginative,sometimes evendangeroussolutions – but“what everyonedoes” offers greatemotionalprotection in a very

difficult profession. It’s easy to forget thatdoctors are people, too!

When people look at these enormoussocial, financial and psychological challenges,they tend to despair and give up. There areno easy solutions to any of those challenges… which is okay!

It’s “okay” because those problems are

NOT the real reason that preventsmedicine from being propelled into thenext century right now.

Medicine fails to live up to its potential –and keeps falling further behind – becauseit is practiced in an old, mid-20th centurymode.

The Reason and the ChanceUp to the 19th century, medicine was

largely unscientific and forever searchingthrough hit-or-miss for the Shotgun Solution– a miracle compound or treatment for“whatever ails you.”

It was the age when medicinal protocolsincluded bloodletting, mercury (if you canbelieve it), cocaine and arsenic.

It also included some very successfulsolutions such as aspirin and sulfur whichare very efficient and have many differentand diverse uses.

The 19th and 20th centuries saw theushering in of the scientific age, and withit, the new “disease-specific” approach.

Researchers started discovering the causesof disease on a microscopic level, and toiledto find means to stop them.

Up to that point, the main killers wereinfectious diseases. Those were found to bethe results of toxicity caused by bacterial orviral presence.

“Whateveryone does”offers greatemotionalprotection in avery difficultprofession.


Above:Edward Jenner (1749 -1823) anEnglish country doctor was thefirst to introduce and study thesmallpox vaccine, the firstsuccessful vaccine everdeveloped. This paved the wayto the practical eradication ofmany infectious diseases whichup to that time would erupt indisastrous pandemics, killingmillions of people.

Left:Doctor inoculating a baby. C.18th century. Painting by LouisLeopold Boilly.

07

Penicillin and other antibiotics areinterventions that kill off the bacterium,thus treating the disease successfully.

As an approach, this is obviously muchmore scientific than the “shotgun” disciplineand, in most cases, far more efficacious.

Theintroductionof powerful,scientificagents causedmany diseasespreviouslyconsideredincurable, likepolio and

tuberculosis, to virtually disappear.

Pandemics which were regularly wipingout almost half of civilization in one fellswoop, such as bubonic plague or measles,became, for the most part, minor nuisances.

But with the eradication of the majorinfectious challenges of past history, thegolden age of the disease-specific approachhas come to an end.

Further progress has become slower andslower still, with problems and limitationscropping up ever more often.

Trying to “fix” conditions with ever moreforceful “shots” creates compounds that doa whole lot more than was intended; namely,

side-effects, many far worse than the diseasesthe drugs come to cure!

But even worse, the forceful approach tomedicine has come up against a foe beforewhich it is almost completely powerless:

Chronic diseases.

Cancer, heart disease, asthma, diabetes,Alzheimer’s, and, indeed all chronic diseasescannot be cured by today’s disease-specificmedicine. In fact, the very mention of theterm “cure” to a doctor immediately raisesserious suspicions of quackery!

The reason chronic diseases defy thedisease-specific approach is because, unlikeinfectious diseases, they cannot be trackeddown to a single cause.

They cannot be summed up as easily,because they are comprised of a large numberof “components” in the form of various sub-processes.

Disease-specific medicine – an “anti-so-and-so-disease pill” – is far too generalized.

It is both too inefficient and harmful tocope with the complex underpinnings ofchronic disease.

Using ever-stronger drugs is akin tolistening to the radio with static noise: Thehigher you turn the volume, the louder thestatic gets. The message doesn’t get anyclearer.

In fact, the verymention of theterm “cure” to adoctorimmediately raisesserious suspicionsof quackery!


Above:Ross Granville Harrison (1870-1959) pursued new methods ofexploration by culturing tissuesoutside the body for the firsttime. His was the first steptoward development of newcancer medications and currentresearch on precursor and stemcells.

Left:Cross-section of a nerve showingnerve fibers organized intobundles (or “fascicles”) enclosedby a band of connective tissuecalled epineurium. Single nervefibers are also enclosed by thinlayers of loose connective tissuecalled endoneurium. The opentubes showing are blood vessels.

09

Luckily, the 21st century is the computerage, which makes a new approach – one thatis tailor-made for chronic diseases – possible.

In fact, new horizons are opening as wespeak.

“Sub-Process Medicine”The world owes the U.S. government a

debt of gratitude it can never repay.

Pointing out governmental ineptitude isa popular spectator sport. Critics were outin droves, jeering loudly at the ultimate“pink elephant” when the U.S. governmentcommissioned the monumental project ofmapping the human genome.

“It will never be finished,” the criticsscoffed. Worse, those experts proclaimed,the U.S. government “idiotically” insistedthat the project be carried out simultaneouslyin many different centers. All the centerswere connected by a network that “obviouslycould never work.”

That network was called Internet and thehuman genome mapping project is, in fact,all but complete.

The “pink elephant” has opened a newworld in many ways.

The time has come to apply those verytools – computer and Internet – to the finalchallenge of making medicine all it can be.

To understand why, let’s explore, for aminute, the makeup of a disease.

The Composition of DiseaseThe “bad news,” as mentioned before, is

that every disease or condition is made upof a number of sub-processes, or “pathways.”

“Diabetes,” “heart disease,” “cancer” andall other diseases are actually general namesgiven to groups of very specific sub-processes,(or “metabolic pathways,” as they are called)that are occurring simultaneously. Forinstance:

Coronary heart disease is a general namegiven to damage caused by compromisedblood flow to the heart. The decreased flowis the result of a general process calledatherosclerosis, or hardening of the arteries.

The hardening of the arteries is caused byseveral sub-processes that occursimultaneously.

One such sub-process is the accumulationof plaque on the arterial walls.

This sub-process may involve the risinglevels of four materials in the body:cholesterol, iron, homocysteine, andinterleukin-6.

These four materials are players in two“sub-sub-processes” that lead to the eventualplaque accumulation.

Milestones in MedicineFirst used in the 19th century,anesthetics continue to evolveand are the most vivid exampleof medicine’s capacity to lessensuffering.

Above:Crawford Williamson Long(1815 – 1878) performed thefirst surgical operation in generalanesthesia induced by ether in1842.

Left:Dr John Collins Warren (secondfrom left) treating a surgerypatient under ether, which waspioneered at the hospital in1846.

11

The first is the oxidation of cholesterol.This happens when the cholesterol iscombined with the excess iron. Onlyoxidized cholesterol molecules form plaque.

The second “sub-sub-process” isinflammation. The walls of inflamed arterieslose their smoothness, attracting the depositsof cholesterol molecules, resulting in plaque.Homocysteine and interleukin-6 either causeor are involved with the inflammatoryprocess.

Each one of those biological sub-processesis a component of the total disease.

The disease “needs” each one of thosecomponents to exist – but how much thedisease is dependent on each sub-processdiffers from process to process and fromperson to person.

Some sub-processes are “10% essential”for the disease. Other processes may carry5%, or 20% or 50% or 80% of theresponsibility.

To alter the course of the disease, the sub-processes must be affected. They must bedecreased, or disrupted, or enhanced, orregulated. The action of altering the sub-process is called pathway modulation.

Pathway modulation is the face of 22ndcentury medicine.

The good news is that this is nothing new.

Medicine has been aware of thecompositional nature of disease practicallysince medicine became a modern science.In fact, this is the basis upon which newdrugs are designed: The processes that makeup the disease are mapped and a drug isformulated to modulate the sub-processesdeemed most crucial for the existence of thedisease.

But even more importantly, all the drugswe already have on hand – whether designedfor it or not – actually modulate processes.

That means thatwe have both themethodology toidentify thosesub-processes aswell as many,many drugs thatefficientlymodulate specificsub-processes.

A second piece of crucial good news is thefact that almost all chronic diseasesactually “share” sub-process with manyother diseases and conditions.

Prostate cancer, lung cancer and arthritisshare an inflammation process caused by anenzyme called COX-2.

Macular degeneration, diabeticretinopathy, colon cancer, and lung cancerall share a common process where too many

Practically alldiseases form an“extendednetwork” bysuch sharing ofsub-processes.

Milestones in MedicineAbove:In 1928, Sir Alexander Fleming(1881 –1955) a Scottish biologistand pharmacologist wasawarded the Nobel Prize inPhysiology or Medicine for hisdiscovery of the antibioticsubstance penicillin.

Left:Spores on the conidiophores ofthe fungus Penicillium notatum.These fungi are the source of theantibiotic Penicillin.

13

blood vessels are created.

AIDS, inflammatory bowel disease, andovarian cancer share an over proliferationof a “guardian protein” called NFkB. NormalNFkB helps regulate the body’s immunesystem. Overabundance of NFkB causesinflammatory and cancerous processes.

Strokes, coughing, prostate cancer, andlung cancer all share an overproduction ofa protein called bradykinin. Bradykinindilates blood vessels and naturally lowersblood pressure. After a stroke, theoverabundance of bradykinin causes aninflammation that results in irreparabledamage to the brain, and death.

The same bradykinin also causes the coughreflex and feeds the cancer process.

Practically all diseases form an “extendednetwork” by such sharing of sub-processes.

The meaning of this – when you throwthe computer into the mix – is nothing shortof staggering.

The Age of IndividualizedMedicine

Research medicine continues to map theinner working of disease, identifying sub-processes and the compounds that willdisrupt them, to the tune of over 40,000published reports a week.

Until now this meant that “we know toomuch.”

First, because no doctor on earth has thetime to look at any more than a few reportsa week – if that.

And second, because the pharmaceuticalcompanies, the conduit to practical medicine,will only touch that which is commerciallyviable.

But the meaning of all this “superfluous”knowledge changes radically the minute wedepart from the old, 20th century disease-specific approach and enter the age of sub-process approach.

Instead of trying to treat a complicateddisease with a single, crude blow of asledgehammer, we now can concentrate ondealing with specific sub-processes of thedisease.

In place of one-drug-per-condition wenow have a choice of ten or more sub-conditions with hundreds of proven drugsto choose from.

The result ismedicine that isexponentiallymore efficient,safe, andinexpensive.

Instead ofpoisoning the

We can nowbegin to “chokeoff” the diseasewith far gentlermeans fromwithin.


Above:French neurologist and surgeonHenri Laborit (1914-1995)discovered in 1952 some of theearliest known tranquilizingdrugs, includingchlorpromazine. The effect ofthis drug in emptyingpsychiatric hospitals has beencompared to that of penicillinand infectious diseases.

Left:“The Cure of Folly”, by Dutchpainter Hieronymus Bosch c.1450 – 1516.

15

patients by pounding diseases with evermore powerful drugs, we can now begin to“choke off” the disease with far gentler meansfrom within.

In fact, when we open up the bank ofknowledge that research medicine hasstashed away, we come up with somestunning revelations and treatments thatwere always there but we never saw them.

For instance:

Suddenly, we find that a very efficientchemotherapeutic treatment for cancers ofthe breast, lung, prostate, ovaries, brain, andlymphomas, to name but a few is … a safe,non-toxic cough suppressant calledNoscapine!

Noscapine has also demonstratedoutstanding clinical effectiveness in reducingthe death rate from strokes.

Additional potential clinical applicationsinclude reversal of morphine-inducedrespiratory depression, and potentiation ofthe pain-relieving effect of morphine by upto threefold!

This is no miracle or old-wives’ tale – thisis pure, sensible scientific knowledge breakingloose of the old, 20th century disease-specificmold.

Noscapine has been known and used sincethe 1880’s!

In-depth studies of Noscapine and itsanticancer properties have been going onfor quite some time in quite a few centersin the world, most notably since 1999 at theEmory University Medical School.

The old, 20th century medicine left thisvery promising treatment undevelopedmainly because Noscapine is not patentable.

It’s easy to be cynical about such reasoning. But reality is that any pharmaceuticalcompany that would have undertaken thecost of FDA-certifying Noscapine for cancertreatment would have stood almost nochance of ever recouping its expenses becauseanyone can sell Noscapine.

But with the advent of the new, 21stcentury networking capabilities, the newsof the trial tests and positive results achievedwith Noscapine has reached many treatingphysicians who use it on their own – withstartling results.

But that is just the tip of the iceberg. Amere harbinger of much grander things tocome.

The MedInsight ProjectWe already know that diseases form a

network by the fact they share identical sub-processes.

As a result, we now have a huge body ofknowledge of options to modulate those

Milestones in MedicineDespite erroneous theories aboutwhat causes disease, new sewagedisposal and water supplysystems in the 1800srevolutionized public health inEurope.

Above:Sir Edwin Chadwick(1800–1890) an English socialreformer who introduced themost dramatic improvement inthe public health. He was acommissioner of theMetropolitan Commission ofSewers in London from 1848 to1849 and commissioner of theGeneral Board of Health fromits establishment in 1848 to1854.

Left:The foundations for a Londonsewer running 20 feet below thesurface of the Essex marshes.

17

processes – with more knowledge comingout of research centers every day.

We also have a very large collection ofdrugs that can do many things – many more,in fact, than they were initially approvedfor. (Noscapine is currently FDA approvedonly as a cough suppressant.)

And – we have a body of patients who,thanks in large part to advertising campaignsfor drugs, have learned to become proactive.They demand their doctors pay attention toinformation they bring in – and in full, 50%of the cases, doctors follow that direction.

We also have doctors who are increasinglymore open to make “unofficial” ex-indicationuse of drugs (use the drugs for conditionsother than those indicated by the FDAlicense).

Almost all the puzzle-pieces needed toinstitute the individualized, sub-process-targeted medicine revolution are in place.

Just one last piece is missing: A systemthat will bring it all together.

A system that will not only contain thevast pool of knowledge of medical researchworldwide but will also process it and makeit instantly usable for any physician andpatient.

That system is called The MedInsightProject.

The MedInsight Project is an internationalnonprofit effort that will supply medicinewith the missing link it needs to make thequantum leap into becoming what otherwisewould take 100 years to achieve – if ever!

The MedInsight Project is comprised of anumber of professional research teams.

Each team will be dedicated to one specificarea of medicine –heart, cancer,diabetes, and so on.Each team will be“researching theresearch” of theirarea of expertise.

In all, over2,000,000 articles ayear will be studiedin depth, theircontents analyzedand processed,mapped, and

indexed into consumer-ready state, availablefor immediate use.

The culled knowledge will be arranged ina perpetually-updating index system thatwill catalogue the information along threeaxes: diseases, sub-processes, and drugs.

Any patient or doctor in the world will beable to log on and start his or her quest forindividualized treatment options simply bytyping the name of the disease.

Almost all thepuzzle-piecesneeded toinstitute theindividualized,sub-process-targetedmedicinerevolution arein place.

Milestones in MedicineOver the past few decades,computers have exploded intoour lives and changed themforever. From decoding thegenome to seeing our body andits functions in threedimensions, computers havechanged the way we heal.

Above:The first computer: Hollerithtabulator and sorter box,invented by Herman Hollerithand used in the 1890 UnitedStates census.

Left:Claudia Mitchell demonstratesthe functionality of hercomputerized thought-controlled 'bionic arm' duringa news conference on September14, 2006 in Washington, DC.

19

The Disease Screen will contain all thecurrent data and latest research paperspublished about the disease.

A single “click” will reveal all the sub-processes known to make up that disease.

Clicking on a sub-process will reveal everydisease that shares the sub-process…

… and all the drugs that effectivelymodulate it.

The results will be medicine that is almostendlessly flexible in adapting itself to theindividual nature of any patient.

Different Strokes forDifferent Folks

Instead of trying to treat the entirecondition with one thunderous, side-effect-laden shot, doctors will be able to map outa strategy of a dozen little things they cando to gently pull threads, as it were, out ofa disease, causing it to dissolve anddisintegrate.

The reason why this approach promises tobe much more efficient than anything we’veseen before is because of the singular natureof every patient.

Though a disease, in general, will showmostly the same sub-processes in everyone,the “importance” of any sub-process to theoverall disease varies from one person toanother.

The same process that is, say, “5%responsible” in patient A’s heart disease mayactually be 50% or 60% responsible for it inpatient B!

That means that when a doctor will givea drug that modulates that specific sub-process to these two patients, the patient Awill experience almost no change whilepatient B will become virtually free of hisheart disease for life!

Further micro-targeting other sub-processesof heart disease will enable the doctor to

keep on “pullingprocesses out” of theequation of thedisease for patient A.

And when the sub-process that holdsthe paramountresponsibility inpatient A’s disease issuccessfullymodulated, he orshe, too, willbecome free of thedisease.

Affordable HealthIndividualized sub-process targeted

medicine will also make treatment of chronicdiseases far less expensive, too.

The collection of proven drugs and

Patient A willexperiencealmost nochange whilepatient B willbecomevirtually free ofhis heartdisease for life!

Milestones in MedicineThe advent of the Internetenabled the establishment ofMedInsight in 2006, giving everydoctor and patient in the worldaccess to untapped treasures ofmedical research.

The use of MedInsight byphysicians will, in turn, supplyefficient medical discoveries withthe combined clinical proof theyneed to enter mainstreammedical protocol.

MedInsight-processedknowledge will makeindividualized medicinepossible, ushering a new dawnof health.

21

therapies we already have and understandis immense. When we shift to micro-targeting of sub-processes, those solutionscan not only efficiently treat manyconditions currently considered to be “deadends” – the treatments will be much lessexpensive.

There will be very limited need to developbigger “cluster bomb” drugs that drive upthe cost of medicine beyond the reach ofmost people.

Intellectual IndependenceThe pharmaceutical companies who know

about The MedInsight Project were quick tooffer funding and sponsorship – only to beturned down.

This, unfortunately, is an absolute must.

The project must take the populist roadto funding because of the profound effectMedInsight’s use will have on the drugindustry.

Pharmaceutical companies will still beable to do what they do best – which ismaking and selling drugs – but new ways ofthinking will have to be adopted.

Few people realize what huge gambles thedevelopment of new hyper-expensivepowerful drugs present to the pharmaceuticalcompanies – and how many of those gamblesthey lose!

With a growing majority of conditionsefficiently treated by existing drugs, thosefunds will become free both to tackleproblems for which we have no solution yet,as well as for the development of moreefficient and ever gentler “micro-drugs.”

Once adjusted, drug companies will bebig winners from the individualized sub-process medicine revolution – but beingforced to do things differently is sure toarouse resistance. The temptation to tamperwill be almost irresistible.

This is why it’s crucial for MedInsight tobe a project for the people, by the people.

MedInsight is a non-profit entity that shallforever remain free to all mankind.

An intellectually-independent MedInsightwill give every doctor on earth his or herown multi-million dollar research team.This will enable him or her to administersuper-efficient, gentle individualizedmedicine to every single patient in the world.

It is the dawn of a whole newworld of medicine.

22

Welcome tothe Age ofIndividualizedMedicine:

23

24

The following are actual clinical cases in whichindividualized medicine was practiced, utilizingMedInsight researched and processed data.

These cases offer a mere glimpse into whatsuddenly becomes possible when we mine theburied knowledge treasures of scientific medicalresearch, unleashing the explosive healingcapabilities of that which is already known.

Soon, with MedInsight, every man, woman andchild in the world will have free and unlimitedaccess to this kind of medicine.

Liver CancerIn 2002, Yam Haya was diagnosed with cancer

of the liver (hepatoblastoma) as a fetus before shewas born. After delivery by c-section, she weighed5.5 pounds (2.5 kg) – of which close to one-fifthwas a 6-inch (15-cm) tumor.

Mainstream Disease-SpecificTreatment:Regular treatments involve surgery where possible,either followed or preceded by aggressivechemotherapy. The chances of survival in infantsare extremely low. Indeed, one expert oncologistadvised that Yam Haya should be allowed to diewithout subjecting her to the agonies of treatment.

In the few cases where children with such cancerssurvive, the chemotherapy usually causes deafnessas well as neurological damage. Yam’s parents wereasked to sign that they understood this before YamHaya received her first chemotherapy session.

Individualized Treatment:Local doctors did not consider surgery an option.Yam Haya was given chemotherapy on her 8th dayof life and almost died from infections caused byit. At this point her parents left the hospital andwent looking for other options.

MedInsight research, however, uncovered evidencethat surgery was Yam’s only chance of survival -while chemotherapy would be useless in her case.

Dr Jean C. Emond, a world-renowned pediatricsurgeon in New York’s Columbia Presbyterian

Hospital agreed to operate, on MedInsight’srecommendation.

Dr. Emond managed to remove the tumor butcould not obtain clean margins (removal of healthytissue around the place of the tumor to ensure nocancer cells were left).

Instead of chemotherapy, baby Yam Haya was givenOGF for two months post surgery, with her parentsinjecting the baby with the drug twice daily. OGFis a substance produced by the body that inhibitsthe division of cancer cells.

Once the tumor marker had dropped to normalnon-cancerous level, treatment was switched tooral low-dose Naltrexone®, which stimulates thebody’s own production of OGF.

Yam Haya also received Noscapine. MedInsightresearch found this non-addictive cough medicinederived from opium that was discovered at EmoryUniversity in 1998 to have anticancer effects athigh doses. Noscapine works in the same fashionas certain chemotherapy drugs, but without theside effects or toxicities.

Yam Haya was also given AHCC.

AHCC, an extract of a Japanese medicinalmushroom, is a biological-response modifier. Ithas been shown in repeated Japanese studies ofpatients with liver cancer to increase the body'sNK (Natural Killer) – the white blood cells thatdestroy virally infected cells, cancer, bacteria,parasites and fungi. Again, AHCC has no sideeffects at dosage used.

Rounding out Yam’s treatment was bovine-sourceColostrum. Studies from Finland of this classicmother’s-milk ingredient have shown its ability toincrease the body's antibody levels which fightdiseases. It was given in this case to help build upthe immune system. Naturally, Colostrum is assafe and side effect-free as mother’s milk.

Epilogue:Yam Haya is a well and healthy child, nearing her5th birthday. There has been no recurrence of thecancer.

1.

“As I have explained tothe parents, based on myextensive medicalexperience, with anymedical therapy knowntoday this case is hopeless.The chances of achievinga complete or partial cureare virtually zero.”

Professor Yoav HornM.D.ChiefDepartment of OncologyAssaf Harofe MedicalCenter, Zrifin, Israel

Individualized Medicine in Action

IT’SPOSSIBLENOW!

25

Metastatic BreastCancerMrs. A. was 54 years old in 2002 when she wasdiagnosed with metastatic breast cancer.

Metastatic breast cancer is incurable, with amaximum life expectancy of about 24 months.Death from metastatic breast cancer is very painful,with patients often bedridden for much of thetime due to untreatable fractures and breakagesof bones.

Mainstream Disease-SpecificTreatment:The treatment for metastatic breast cancer thattoday’s disease-specific medicine employs ischemotherapy to shrink tumors. The side effectsof chemotherapy are nausea, vomiting, hair loss,fatigue, neurological symptoms, low blood counts,l i fe - threatening infect ions and death.

As the pain inevitably intensifies, patients receiveincreasing doses of opiates. The opiates causeconstipation and loss of lucidity. As resistancesets in, dosages need to be raised constantly.

Individualized Treatment:Instead of receiving the usual treatment, Mrs. A.

has received individualized, sub-process treatment.

The individualized treatment of Mrs. A. includedfour conventional drugs – none of which is a partof “accepted protocol” treatment of cancer.

The first targeted treatment she received is calledOGF (Opioid Growth Factor). OGF is a substancethat is produced by the body itself to slow thedivision rate of cancer cells. Its administrationenables the body, as well as other agents, toeffectively attack the cancer. It has very minorside effects.

The second treatment was the drug Noscapine.

Noscapine is a cough medicine derived fromopium. In 1998, it was discovered at EmoryUniversity to have anticancer effects at high doses.It works in the same fashion as certainchemotherapy drugs, but without the side effectsor toxicities.

The third drug used in the treatment of Mrs. A.was Dipyridamole®.

Dipyridamole® inhibits the formation of bloodclots. It, too, is an old drug approved in the 1960'sfor treating angina and cardiovascular disease.Dipyridamole® prevents platelets from stickingtogether to form clots. Extensive laboratory workhas shown Dipyridamole® to have anticanceractivity.

2.

“As the one whoreferred Mrs. A. toMedInsight’s founder forconsultation, I amespecially gratified by theincredible results whichMrs. A. has achieved.Thankfully, this hasenabled her to continueto be part of our team atthe Ministry of Health,and my sincere hope isthat all cancer patientsshould be able to availthemselves of suchsuccessful treatmentapproaches.”

Mrs. Simcha BookProject ManagerHealth InformationServicesState of Israel Ministry ofHealth


IT’SPOSSIBLENOW!

26

Possible side effects of Dipyridamole® are transientheadaches and digestive disturbances that arenegligible in comparison to chemotherapy andsafe for long-term use.

The last drug in Mrs. A.’s individualized treatmentwas Heparin®.

Low-Molecular Weight Heparin® (LMWH) is a drugused to break down clots and prevent reformationof clots after the treatment. Numerous reportshave shown a positive effect on prolongation ofsurvival in cancer patients, via several mechanisms.Heparin® has recently been shown to be a directcytotoxic (i.e., it kills cancer cells like chemotherapydoes).

Heparin® is a generally safe drug, with rare,reversible bleeding episodes (less than 1%). Long-term use can contribute to osteoporosis unlesscalcium and vitamin D are taken regularly.

Epilogue:Five years later, Mrs. A. is alive and well. Herdisease is in remission and she continues to leadan active lifestyle, going to work daily. Whilesuch rare remissions are known to be possible,Mrs. A. – and other patients – are achieving themwith none of the side effects experienced by cancerpatients who go through today’s disease-specific“normal” cancer t rea tment protocol .

Notes:The anticancer properties of Noscapine have beenknown for a while and individual doctors aroundthe world have been using it successfully.

Since Noscapine is non-patentable, nopharmaceutical company was going to invest thefunds necessary to approve it for cancer treatment.Currently Emory University has managed to patenta synthetic form of Noscapine for cancer and thiswill be entering clinical trials in the coming years.

Thousands of drugs, procedures and treatments,many startlingly beneficial, form the hiddentreasures of the medical world, destined never tomake it to “the street.” The general public is deniedaccess to them for reasons totally unrelated toeffectiveness.

The introduction into clinical use of extraordinarydrugs and treatments for cancer such as OGF,Noscapine, Dipyridamole®, and Heparin® is one ofthe prime benefits of the MedInsight system.

Access to those discoveries allows doctors to thinkof diseases as a set of sub-processes instead of asingle condition to be treated. This ushers in theage of individualized medicine that’s tailor-madeto fit the individual patient.

27

Metastatic PancreaticCancer

Pancreatic cancer is considered one of thespeediest killer cancers known. The disease isincurable with an average 3-month survival rateonce it has metastasized. Patients are usually sentto hospice very quickly since the pain is sodevastatingly debilitating.

Mrs. P.W., a 79-year-old Holocaust survivor, wasdiagnosed with metastatic pancreatic cancer inAugust 2006. The cancer had spread to the liverand vascular system, causing the patient severeagony. Mrs. P.W. was put on numerous anti-painmedications which offered little relief. Sheexperienced severe weight loss.

Mainstream Disease-SpecificTreatment:The usual disease-specific treatment for pancreaticcancer includes three agents:

Chemotherapy is administered in an attempt toshrink the tumor for a short while. The side effectsof chemotherapy are nausea, vomiting, hair loss,fatigue, neurological symptoms, low blood counts,l i fe threatening infections and death.

Radiation is used in an attempt to shrink tumorswhich are causing pain. The side effects of radiationare burns, fibrosis, organ damage, low blood countsand life-threatening infections.

Narcotics are administered for pain. Their sideeffects include constipation and loss of mentallucidity. The dosages of the narcotics mustconstantly be raised as resistance sets in.

Individualized Treatment:Extensive MedInsight research has revealed anumber of little-known agents. These were utilizedto treat Mrs. P.W.

The first was celiac plexus block, a procedure ofinjecting alcohol into the nerve near the pancreas.Multiple sources reveal that celiac block often getsrid of most of the pain of pancreatic cancer!

According to Dr. Peter Mueller of the MassachusettsGeneral Hospital in Boston, “celiac plexus blockis an effective tool for pain management that hasbeen traditionally overlooked. … Complicationsare infrequent. After this procedure, patients withcancer generally report partial or completesymptomatic pain relief for the remainder of theirlives.”

Next Mrs. P.W. was administered OGF infusions.

3.

“These results arepractically unheard of inmetastatic pancreaticcancer. They demonstratethe enormous hiddenpotential which exists fortreating such cases usingan approach whichintegrates the masses ofwidely-unpublicizedmedical knowledge andresearch.”

Dr. Etienne CalleboutM.D.Specialist in OncologyHarley Street, London,United Kingdom


IT’SPOSSIBLENOW!

28

OGF is a substance produced by the body thatslows the division rate of cancer cells, thus enablingthe body and/or other agents to effectively attackthe cancer. OGF has been shown in a clinical trialat Penn State University to double survival timein pancreatic cancer patients.

There are no side effects to OGF at doses used.

The third agent was oral administration ofImiquimod®.

Imiquimod® is a cancer drug used for treating skincancer. MedInsight research revealed that studiesshow Imiquimod® increases the receptors for OGF.This can potentiate the effect of OGF exponentially,making it far more effective than whenadministered alone. There are no side effects toImiquimod® at the dosages used.

Mrs. P.W. was also given Tarceva®, a biologicaldrug developed to treat lung cancer. The drug isused at a very low dose since MedInsight hasidentified a way to greatly increase its absorption.

Possible side effects of Tarceva® in the dosages usedinclude only skin rash and transient diarrhea.

Omegaven® (intravenous fish-oil infusion) wasintroduced because MedInsight research indicatedclinical trials that show it to reverse weight lossin pancreatic cancer patients. Omegaven® has no

side effects whatsoever.

Antabuse®, a 60-year-old drug used to preventalcohol-abuse, was added at a low dose since ithas been revealed to have potent anticancer effectin experimental studies as well as in a number ofcase reports. While Antabuse® is designed to havehorrible side effects if taken with alcohol, thereare none when taken otherwise.

Lastly, Thioctic Acid infusions were introduced.Thioctic Acid is a drug used in Europe as atreatment for some complications of diabetes. Itis a very powerful antioxidant and liver regenerator.U.S. case reports have shown a few cases of long-term survival in pancreatic cancer patients usingit. (Infusions must be administered gradually astoo quick infusions of Thioctic Acid result inhypoglycemia.)

Epilogue:Mrs. P.W. is alive and well over one year aftercommencing individualized treatment. She istotally free of pain. The patient regained her pre-ailment weight and kept it stable. She has notrequired even one day of hospitalization!

Mrs. P.W. has been able to participate in hergrandchild's wedding.

29

Multiple SclerosisIn 1989 A. was 28 when he was diagnosed withMS. The deterioration in his condition was gradualwith acute attacks.

Multiple Sclerosis (MS) is an incurable autoimmunedisease.

The manifestations of MS are muscle weaknessthat causes difficulty walking, as well as loss ofcoordination or balance, numbness, feelings of"pins and needles," or other abnormal sensations.

Patients with MS also have problems with vision(including blurred or double vision), fatigue, musclestiffness, tremors (shaking), paralysis, pain, vertigo(dizziness, light-headedness), and difficulty withspeech and/or swallowing. They often experienceloss of bowel or bladder control, constipation andsexual problems, as well as changes in their abilityto think clearly.

Mainstream Disease-SpecificTreatment:Current mainstream treatment for MS includesthe drugs Betaseron®, Avonex® and Copaxone®.

The efficacy of those drugs is summed up ratherbluntly by this excerpt from a New York Timesarticle:

"… But doctors also acknowledge that thetreatments can be difficult. The drugs cost $1,000a month (in the U.S.) and must be given byinjection – daily, every other day or once a week,depending on the drug. The course of treatmentis indefinite, probably lifelong. The interferonscan cause flu-like fever, chills and aches, and painand swelling at the injection site. For all thattrouble, the drugs do not cure the disease and maynot make people feel better."

Individualized Treatment:MedInsight-uncovered therapies were administeredto A. during an especially acute attack.

The therapy suggested was the drug Naltrexone®,an anti-opiate-addiction drug.

Low dose of Naltrexone®, less than 5% of the doseused to treat drug addiction, is effective in inducingremission in many autoimmune diseases. It doesso by raising the body's endorphin levels whichregulate the immune system. Side effects ofNaltrexone® are uncommon and include transient,mild insomnia which lasts a few days.

(This effect is achieved only with low dose use.Regular dose used for treatment of addiction wouldactually make MS much worse!)

His doctor, who was present during the attack,ordered A. hospitalized on the spot despite havingagreed to commence the MedInsight-suggestedprotocol. A., however, began feeling better within6 hours of taking the Naltrexone® and avoided theneed for hospitalization.

Epilogue:Treatment is continuing presently. The MS wentinto remission. The limping which had been goingon for 4 years has disappeared. The patient feelsmore awake and alert than he had since diagnosis.


IT’SPOSSIBLENOW!

4.

“I am delighted thatmy patient has achievedsuch fantastic results insuch a short time period,utilizing what isessentially a non-toxictherapy. I have since usedthis same therapy in otherpatients with excellentresults.”

Dimitrios Karussis, M.D.,Ph.D.Professor of Medicine,Department of NeurologyHadassah UniversityHospitalJerusalem, Israel

30

Crohn’s DiseaseMedInsight-unveiled treatment was used on agroup of 17 patients, suffering moderate to severeCrohn's disease for which regular immunesuppressing therapies proved inefficient. Theirages ranged from 23 – 63.

Crohn’s disease is considered an incurable andextremely debilitating disease in which ahypersensit ized immune system causesinflammation of the gastrointestinal system.

Major symptoms of Crohn’s disease includeabdominal pain, diarrhea, gastrointestinal bleeding,intestinal blockage and malabsorption. Patientssuffer from weight loss and fistulas, oftennecessitating recurrent surgeries which result inshort bowel syndrome, sometimes requiringintravenous feeding for life.

Mainstream Disease-SpecificTreatment:Common, disease-specific treatment for Crohn’sdisease includes a variety of drugs such as steroids,Remicade®, Methotrexate® and Cyclosporine®, all

of which are used to suppress immunity in anattempt to suppress the inflammation.

Individualized Treatment:MedInsight uncovered that the same anti-addictiondrug Naltrexone® that was so successful in treatingMS was equally efficient in treating the underlyingsub-processes of Crohn’s disease.

Naltrexone® does this by raising the body'sendorphin levels which regulate the immunesystem. Like in MS, this effect is only achievedwith low dose use. Regular dose which is used fortreatment of addiction actually would make thecondition much worse.

The group of patients experienced an 89% responserate and 67% of the group entered remission.

The study of the MedInsight-recommended therapywas conducted by Dr. Jill Smith, Professor ofMedicine at Hershey Medical Center of Penn StateUniversity.

Results of the study were published in theprestigious medical journal American Journal ofGastroenterology.

5.

“This is a novel, yeteffective approach, totreating a commondisease.”

Jill P. Smith, M.D.Professor of Medicine,Gastroenterology &HepatologyHershey Medical Center,Penn State UniversityHershey, Pennsylvania,USA


IT’SPOSSIBLENOW!

31

Medical Advisory Board

32

Ian S. Zagon, Ph.D.Chairman

Distinguished ProfessorHershey Medical Center, Penn State University

Hershey, Pennsylvania, USA

Israel Barken, M.D., FACSClinical Professor, Department of Urology

University of California, San DiegoLa Jolla, California, USA

*Etienne Callebout, M.D.

Pinero HouseHarley Street

London, United Kingdom

*Raymond H. Chang, M.D., FACP

Medical DirectorMeridian Medical GroupNew York, New York, USA

*Olga V. Galkina-Taylor, Ph.D.

Research DirectorNeuro-Lab Ltd

Bournemouth, United Kingdom

*David Goldenberg, M.D.

Director of Head and Neck SurgeryHershey Medical Center, Penn State University


*Steven R. Goodman, Ph.D.

Professor, Molecular and Cell BiologyEditor-in-Chief, Experimental Biology and Medicine

University of Texas at DallasRichardson, Texas, USA

*Dimitrios Karussis, M.D., Ph.D.

Professor of Medicine, Department of NeurologyHadassah University Hospital

Jerusalem, Israel

Patricia McLaughlin, Ph.D.Professor, Neural and Behavioral Sciences

Hershey Medical Center, Penn State UniversityHershey, Pennsylvania, USA

*Peter L. Pedersen, Ph.D.

Professor, Biological ChemistryJohns Hopkins University School of Medicine

Baltimore, Maryland, USA

*Theodore A. Slotkin, Ph.D.

Professor, Pharmacology, Psychiatry and NeurobiologyDuke University Medical Center

Durham, North Carolina, USA

*Jill P. Smith, M.D.

Professor of Medicine, Gastroenterology and HepatologyHershey Medical Center, Penn State University


*David E. Stein, M.D., FACS

Chief, Division of Colorectal SurgeryHahnemann University HospitalPhiladelphia, Pennsylvania, USA

*Robert A. Wild, M.D., Ph.D.

Professor of Medicine, Reproductive EndocrinologyHealth Sciences Center, Oklahoma University

Oklahoma City, Oklahoma, USA

*Joseph Yanai, Ph.D.

Professor, Anatomy and Cell BiologyThe Hebrew University-Hadassah Medical School

Jerusalem, Israel

How to InstantlyAdvance Medicine

by 100 Years

The MedInsight Project

MedInsight Research Institute is a registered US 501(c)(3) nonprofit organization and a registered UK charity whose mission is to save lives and ease suffering.

In the US:MedInsight Research Institute211 East Lombard Street, #297Baltimore, MD 21202, USA

In the UK:MedInsight Research Institute TrustIsland West, Steep, Hampshire,GU32 1AE, United Kingdom

In Israel:MedInsight Research Institute27 Yitzchak Street, POB 386,Telz Stone 90840, Israel

Tel: +1-443-927-7755Fax: [email protected]

Tomorrow’s Medicinefor Anyone, Anytime, Anywhere

MedInsightr e s e a r c h i n s t i t u t e

®

medinsight catalogue

Documents

research medicine

thats medicine

ofusable medical research

r c h i n s t i t u

anywheremedinsightr

registered uk charity

pancreatic cancer patients

breast cancer patients